Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Tintelnot J, Stein A, Al-Batran SE, Ettrich T, Götze T, Grün B, Haag GM, Heuer V, Hofheinz RD, Homann N, Bröring TS, Cruz MS, Kurreck A, Lorenzen S, Moosmann N, Müller C, Schuler M, Siegler G, Binder M, Gökkurt E. Tintelnot J, et al. Among authors: hofheinz rd. Front Oncol. 2023 Oct 16;13:1272175. doi: 10.3389/fonc.2023.1272175. eCollection 2023. Front Oncol. 2023. PMID: 37909020 Free PMC article.
Oncology in Europe.
Lordick F, Lorenzen S, Hofheinz R. Lordick F, et al. Oncol Res Treat. 2023;46(9):345-347. doi: 10.1159/000529681. Epub 2023 Feb 13. Oncol Res Treat. 2023. PMID: 36780881 Free article. No abstract available.
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I, Hirsch D, Ceribas Y, Weidner P, Weichert W, Götze TO, Perner S, Luley K, Heyer CM, de la Torre C, Hofheinz RD, Lorenzen S, Gaiser T. Porth I, et al. Among authors: hofheinz rd. Eur J Cancer. 2023 Apr;183:119-130. doi: 10.1016/j.ejca.2023.01.022. Epub 2023 Feb 3. Eur J Cancer. 2023. PMID: 36848831 Free article.
Pancreatic, Hepatic, and Biliary Tract Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023.
Heise C, Nieto AE, Scheck MK, Ekmekciu I, Sommerhäuser G, Reinacher-Schick A, Hofheinz RD, Lorenzen S, Wege H, Kunzmann V, Götze TO, Mavroeidi IA. Heise C, et al. Among authors: hofheinz rd. Oncol Res Treat. 2024;47(5):233-237. doi: 10.1159/000537935. Epub 2024 Feb 22. Oncol Res Treat. 2024. PMID: 38387453 Free article. No abstract available.
Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023.
Scheck MK, Ekmekciu I, Sommerhäuser G, Heise C, Mavroeidi IA, Kunzmann V, Wege H, Reinacher-Schick A, Hofheinz RD, Oliver Götze T, Lorenzen S, Nieto AE. Scheck MK, et al. Among authors: hofheinz rd. Oncol Res Treat. 2024;47(5):224-228. doi: 10.1159/000538324. Epub 2024 Mar 13. Oncol Res Treat. 2024. PMID: 38479362 Free article. No abstract available.
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Piringer G, Thaler J, Anchisi S, Geffriaud-Ricouard C, Gueldner M, Scholten F, Derigs HG, Bohanes P, Grünberger B, Schwarz L, von Moos R, Hofheinz RD. Piringer G, et al. Among authors: hofheinz rd. J Geriatr Oncol. 2023 Nov;14(8):101638. doi: 10.1016/j.jgo.2023.101638. Epub 2023 Sep 28. J Geriatr Oncol. 2023. PMID: 37776611
Survival Among Patients Treated with Total Mesorectal Excision or Selective Watch-and-Wait After Total Neoadjuvant Therapy: A Pooled Analysis of the CAO/ARO/AIO-12 and OPRA Randomized Phase II Trials.
Williams H, Fokas E, Diefenhardt M, Lee C, Verheij FS, Omer DM, Lin ST, Dunne RF, Marcet J, Cataldo P, Polite B, Piso P, Polat B, Dapper H, Ghadimi M, Hofheinz RD, Qin LX, Saltz LB, Wu AJ, Gollub MJ, Smith JJ, Weiser MR, Rödel C, Garcia-Aguilar J; German Rectal Cancer Study Group; OPRA Consortium. Williams H, et al. Among authors: hofheinz rd. Ann Oncol. 2025 Jan 21:S0923-7534(25)00010-9. doi: 10.1016/j.annonc.2025.01.006. Online ahead of print. Ann Oncol. 2025. PMID: 39848335
Differential effects of sound interventions tuned to 432 Hz or 443 Hz on cardiovascular parameters in cancer patients: a randomized cross-over trial.
Hohneck A, Rodríguez ÁM, Weingärtner S, Merx K, Sarodnick F, von Gagern F, Mavratzas A, Burkholder I, Schumacher G, Hofmann WK, Hofheinz RD. Hohneck A, et al. Among authors: hofheinz rd. BMC Complement Med Ther. 2025 Jan 22;25(1):18. doi: 10.1186/s12906-025-04758-5. BMC Complement Med Ther. 2025. PMID: 39844155 Free PMC article. Clinical Trial.
228 results